|
|
|
Delayed
Hong Kong Stock Exchange
-
03:21 2022-07-05 am EDT
|
|
50.40 |
HKD
|
|
-0.59%
|
|
|
|
|
|
|
| Most relevant news about REMEGEN CO., LTD. |
|
|
| 05/05 | RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire.. | CI |
| 04/28 | RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon | MT |
| 04/27 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 04/12 | RemeGen Co., Ltd. Announces Executive Changes | CI |
| 04/11 | UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108 | MT |
| 03/31 | RemeGen Lists in Shanghai's STAR Market | MT |
| 03/22 | RemeGen Prices Shanghai IPO to Raise $410 Million | MT |
| 02/20 | RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise.. | MT |
| 02/20 | RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 20.. | CI |
| 01/25 | Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of .. | CI |
| 01/24 | RemeGen Completes Phase 2 Trial of Sjögren's Syndrome Treatment in China | MT |
| 01/24 | RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patie.. | CI |
| 01/12 | Chinese Regulator Approves RemeGen's Shanghai IPO Application; Shares Jump 9% | MT |
| 01/05 | Chinese Regulators Grant Conditional Marketing Approval to Remegen's Urothelial Carcino.. | MT |
| 01/05 | RemeGen Co., Ltd. Announces National Medical Products Administration Grants Conditional.. | CI |
| |
|
| All news about REMEGEN CO., LTD. |
|
|
| |
|
| News in other languages on REMEGEN CO., LTD. |
|
|
| |
|
| Analyst Recommendations on REMEGEN CO., LTD. |
|
|
| |
|
|
|
|
China's biotech sector comes of age with big licensing deals, global ambitions |
|
|
|
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
